Does Medicare Cover Zepbound in 2026?
- Dr. Shukhman
- Jun 30
- 4 min read
For the first time, eligible Medicare Part D patients may be able to access a GLP-1 medication for weight management for no more than $50 per month. If cost has been the reason you or a patient has been waiting, that barrier is about to drop significantly.
Here is what you need to know about how this works, who qualifies, and what to do next.
What Is the Medicare GLP-1 Bridge Program?
Eli Lilly launched the Medicare GLP-1 Bridge program, effective July 1, 2026. Under this program, eligible Medicare Part D patients can access one of two FDA-approved weight management medications at a capped cost of $50 per month.
This is the first time Medicare Part D has offered broad coverage for a GLP-1 medication specifically for overweight or obesity. Previously, Medicare coverage for these drugs was limited to patients with qualifying conditions like type 2 diabetes or cardiovascular disease.
Which Medications Are Covered?
Two Lilly medications are included in the program:
Zepbound (tirzepatide) KwikPen is a once-weekly injectable. It works on two appetite-related hormone pathways, GIP and GLP-1, making it a dual receptor agonist. It is currently the most prescribed injectable weight management medication in the United States.
Foundayo (orforglipron) is a once-daily oral pill. It is a GLP-1 receptor agonist taken by mouth, with no injection required and no food or timing restrictions. It works on a single hormone pathway and uses a different molecular structure than tirzepatide.
These are two distinct drugs with different mechanisms and different efficacy profiles. The right choice depends on your medical history, other medications, and your treatment goals. Your physician can help you determine which is the better fit.
Who Qualifies for the $50 Cap?
Eligibility criteria are defined by CMS and are based on two factors:
BMI meeting the threshold for obesity or overweight with a related complication
Select obesity-related complications, such as hypertension, type 2 diabetes, obstructive sleep apnea, cardiovascular disease, or other qualifying conditions
You must also have active Medicare Part D coverage. The program applies to LillyDirect Pharmacy and participating retail pharmacies.
How Does the Process Work?
The prior authorization process is straightforward:
Format: 12 multiple-choice questions, submitted digitally through CMM or by fax
Turnaround: Most PA determinations come back within 24 to 72 hours
What patients need: Their Medicare Beneficiary Identifier (MBI), which can be found on their Medicare card
Fill options: If approved, patients can fill at LillyDirect Pharmacy or transfer to any preferred local retail pharmacy
The MBI is the key piece of information. Patients should have it ready when prompted during the LillyDirect process.
A Note on Choosing the Right Medication
Zepbound and Foundayo are not interchangeable. Zepbound is a dual-receptor agonist that has produced average weight loss of 15 to 20 percent in clinical trials. Foundayo is a single-receptor GLP-1 agonist with average weight loss of approximately 12 percent at the highest dose in comparable trials.
For patients already doing well on a tirzepatide-based medication, staying on that treatment is generally the right clinical decision. For patients who have not yet started GLP-1 treatment, or who prefer an oral option, Foundayo may be a practical starting point.
This is not a decision to make based on what is most convenient or what is being marketed most aggressively. It is a decision to make with a physician who knows your history.
At White Olive, I work with patients across Calabasas, Woodland Hills, Westlake Village, Agoura Hills, and Malibu who are navigating exactly these kinds of decisions. Obesity medicine requires more than a prescription. It requires a plan that fits the person.
Frequently Asked Questions
Does Medicare cover Zepbound in 2026?
Starting July 1, 2026, eligible Medicare Part D patients may be able to access Zepbound KwikPen for no more than $50 per month through Lilly's Medicare GLP-1 Bridge program. Eligibility is based on BMI and select obesity-related complications as defined by CMS.
What is Foundayo and is it the same as Zepbound?
No. Foundayo (orforglipron) is a once-daily oral pill and a GLP-1 receptor agonist. Zepbound (tirzepatide) is a once-weekly injectable dual GIP/GLP-1 receptor agonist. They are two different medications from the same manufacturer with different mechanisms, different efficacy profiles, and different use cases.
How do I know if I qualify for the Medicare GLP-1 Bridge program?
You need active Medicare Part D coverage, a BMI that meets CMS criteria, and at least one qualifying obesity-related complication. A physician who practices obesity medicine can review your eligibility and submit the prior authorization on your behalf.
Can I use my regular pharmacy if I qualify?
Yes. If your prior authorization is approved, you can fill your prescription at LillyDirect Pharmacy or transfer to any preferred local retail pharmacy.
What do I need to have ready to start the process?
Your Medicare Beneficiary Identifier (MBI). This is printed on your Medicare card. You will be prompted to provide it when going through LillyDirect.
If you are a Medicare patient in the Calabasas, Westlake Village, or Woodland Hills area and want to understand whether you qualify for this program, I am happy to walk through that with you.
Comments